Patent
Method of effecting neuroprotection using soluble neuregulin isoforms (US Patent 10813978)
Mind-NRG Sàrl · Granted Oct 27, 2020 · Filed May 23, 2019
Patent number: 10813978 Kind code: B2 Granted: 2020-10-27 Filed: 2019-05-23 Inventors: André Schrattenholz (Mainz, DE) Assignees: Mind-NRG Sàrl (Geneva, CH)
Abstract
The present invention refers to soluble Neuregulin-1 isoforms representing Posttranslational Neuregulin-1 modifications as medication in cognition-related neurological disorders, in particular schizophrenia, Alzheimer's and Parkinson's diseases.
Claims
- A method of treating a subject suffering from traumatic brain injury,
Showing a preview — retrieve the full document via the Exa API.
Powered by the Exa API